Acetaminophen (APAP) is a clinically important drug that is widely used for its analgesic and antipyretic properties. Historically, chronic treatment with therapeutic doses has been presumed safe; however, a recent clinical trial showed evidence of hepatotoxicity in healthy adults using the maximum recommended daily dose for two weeks. These results raise particular concerns with respect to the elderly because many older patients rely on APAP to alleviate chronic pain. Additionally, aging is accompanied by changes in liver function, and hepatic drug metabolism is a key mediator of APAP-induced liver injury. We are using a mouse model to investigate the possibility of hepatotoxicity, adaptive responses, and age-dependent outcomes produced by chronic, low-dose APAP treatment.
Honors & Awards
- HHMI-Sponsored University of Utah Med Into Grad Program Scholarship (2012 – 2014)
- American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship (2012 – 2014)